Menu
← Oncology Approval Tracker
FDA DECISION ·
Darzalex Faspro + VRd
daratumumab and hyaluronidase-fihj with bortezomib, lenalidomide and dexamethasone · Janssen Biotech
Open LinkedIn brief ↓1 min read · estimated
APPROVED USE
What FDA approved
Adults with newly diagnosed multiple myeloma who are ineligible for autologous stem-cell transplant.
LAMPGEN ANALYSIS
Why it matters
This adds a CD38 antibody to an established three-drug backbone for transplant-ineligible patients. The FDA distinguishes transplant ineligibility from patients who declined transplant in the study.
What research teams should watch
Record the reason for transplant ineligibility, then coordinate route, cycle timing and safety monitoring across four agents.
PRIMARY RECORDS